APT THERAPEUTICS, INC.

Address

4041 Forest Park Avenue
SAINT LOUIS, MO, 63108-3213

Information

DUNS: 192266141
# of Employees: N/A

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. Antithrombotic Therapy with No Bleeding Risk for PCI

    Amount: $300,437.00

    Adjunctive antithrombotic treatment with dual antiplatelet therapy aspirin P Y antagonist plus anticoagulant heparin or bivalirudin is a guideline mandated for percutaneous coronary interven ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  2. IL2-based Immunotherapy for Type 2 Diabetes

    Amount: $299,200.00

    DESCRIPTION provided by applicant Principal Investigator Program Director Last First Middle Chen Ridong Abstract Type diabetes T D is a leading cause of cardiovascular disease renal failu ...

    SBIRPhase I2016Department of Health and Human Services
  3. IL2-based Immunotherapy for Lupus

    Amount: $225,000.00

    Systemic lupus erythematosus SLE is a prototypic autoimmune disease that affects at least million Americans Current immunosuppressive treatments are effective but can be accompanied by infect ...

    SBIRPhase I2016Department of Health and Human Services
  4. Human Apyrase Therapy for Acute Ischemic Stroke

    Amount: $968,157.00

    Principal Investigator Program Director Last First Middle Chen Ridong Abstract There remains a crucial unmet medical need in acute ischemic stroke AIS treatment Approximately of p ...

    SBIRPhase II2016Department of Health and Human Services
  5. Optimized IL2-based Therapy for Type 1 Diabetes

    Amount: $298,486.00

    DESCRIPTION provided by applicant Type diabetes is an immune mediated disease in which insulin producing beta cells are destroyed resulting in life long dependence on exogenous insulin The numb ...

    SBIRPhase I2015Department of Health and Human Services National Institutes of Health
  6. Low-dose IL-2-based Immunomodulatory Therapy for PAH

    Amount: $297,410.00

    DESCRIPTION provided by applicant Despite evidence that inflammatory mechanisms initiate and complicate pathophysiology in pulmonary arterial hypertension PAH no strategies have been developed ...

    SBIRPhase I2015Department of Health and Human Services National Institutes of Health
  7. Human Apyrase Therapy for Diabetic Neuropathic Pain

    Amount: $299,793.00

    DESCRIPTION provided by applicant Neuropathic pain such as diabetic neuropathic pain DNP can be difficult to treat with only of patients achieving meaningful andgt pain relief Cu ...

    SBIRPhase I2015Department of Health and Human Services National Institutes of Health
  8. Manufacturing of Growth Factors to Enable Cardiopoietic Stem Cell Therapy for Hea

    Amount: $224,139.00

    DESCRIPTION (provided by applicant): Cardiopoietic cell therapy significantly improved left ventricular function, blunted pathological remodeling, and functional outcomes in animal models and Phase I/ ...

    SBIRPhase I2014Department of Health and Human Services
  9. Low-dose IL2-based Immunomodulatory therapy for Stroke

    Amount: $224,879.00

    DESCRIPTION (provided by applicant): It has been recently shown that CD4+ and CD8+ T lymphocytes are critically involved in the collateral brain injury and neurological deficit associated with experim ...

    SBIRPhase I2014Department of Health and Human Services
  10. Magnetic Flow Sorter for Pancreatic Islet Isolation

    Amount: $288,298.00

    DESCRIPTION (provided by applicant): Bone metastasis is common in patients with advanced breast, prostate, and lung cancers as these tumors have a remarkable ability to metastasize to bone. Two-thirds ...

    SBIRPhase I2013Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government